Michael Cherny
Stock Analyst at Leerink Partners
(4.37)
# 351
Out of 5,128 analysts
111
Total ratings
61.18%
Success rate
14.79%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CERT Certara | Upgrades: Outperform | $13 | $9.67 | +34.44% | 2 | Jan 6, 2026 | |
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $177.74 | +18.15% | 3 | Oct 21, 2025 | |
| MCK McKesson | Maintains: Outperform | $785 → $850 | $814.63 | +4.34% | 15 | Sep 24, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $202.49 | -8.14% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $27.43 | +2.08% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.31 | +129.01% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $23.62 | -2.62% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $600.02 | -45.00% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $33.87 | +18.10% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $80.60 | -6.95% | 11 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $90 | $43.74 | +105.76% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $170.58 | +64.15% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $79.00 | +6.33% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $243.19 | +1.98% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $188.22 | +35.48% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.48 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $335.74 | -18.09% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $254.67 | +2.09% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.79 | +186.74% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.61 | +123.39% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $2.36 | +2,124.58% | 2 | Jan 5, 2022 |
Certara
Jan 6, 2026
Upgrades: Outperform
Price Target: $13
Current: $9.67
Upside: +34.44%
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $177.74
Upside: +18.15%
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $814.63
Upside: +4.34%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $202.49
Upside: -8.14%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $27.43
Upside: +2.08%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.31
Upside: +129.01%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $23.62
Upside: -2.62%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $600.02
Upside: -45.00%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $33.87
Upside: +18.10%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $80.60
Upside: -6.95%
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $43.74
Upside: +105.76%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $170.58
Upside: +64.15%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $79.00
Upside: +6.33%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $243.19
Upside: +1.98%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $188.22
Upside: +35.48%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $12.48
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $335.74
Upside: -18.09%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $254.67
Upside: +2.09%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.79
Upside: +186.74%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.61
Upside: +123.39%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $2.36
Upside: +2,124.58%